Moderna
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2010-01-01
- Employees
- 5.6K
- Market Cap
- $30.3B
- Website
- http://www.modernatx.com
- Introduction
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults
- Conditions
- Prevention of Chikungunya Virus Infection
- Interventions
- Other: PlaceboBiological: mRNA-1944
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2021-07-07
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT03829384
- Locations
- 🇺🇸
PPD Phase 1 Clinical Research Unit, Austin, Texas, United States
Open Label Study of mRNA-3704 in Patients With Isolated Methylmalonic Acidemia
- Conditions
- Metabolism, Inborn ErrorsMethylmalonic Acidemia (MMA)
- Interventions
- Biological: mRNA-3704
- First Posted Date
- 2019-01-22
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- ModernaTX, Inc.
- Registration Number
- NCT03810690
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies
- Conditions
- Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC LymphomaDose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma
- Interventions
- Biological: mRNA-2752Biological: Durvalumab
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 134
- Registration Number
- NCT03739931
- Locations
- 🇺🇸
The University of Chicago Medicine, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
"The MaP Study": Mapping the Patient Journey in MMA and PA
- Conditions
- Propionic AcidemiaMethylmalonic Acidemia
- First Posted Date
- 2018-04-02
- Last Posted Date
- 2021-08-02
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 97
- Registration Number
- NCT03484767
- Locations
- 🇺🇸
Stanford Health Services, Stanford, California, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults
- Conditions
- Human Metapneumovirus and Human Parainfluenza Infection
- Interventions
- Other: PlaceboBiological: mRNA-1653
- First Posted Date
- 2018-01-08
- Last Posted Date
- 2020-02-06
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 124
- Registration Number
- NCT03392389
- Locations
- 🇺🇸
Meridian Clinical Research, LLC, Omaha, Nebraska, United States
🇺🇸Benchmark Research, Fort Worth, Texas, United States
Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults
- Conditions
- Cytomegalovirus Infection
- Interventions
- Biological: mRNA-1647Biological: mRNA-1443Other: Placebo
- First Posted Date
- 2017-12-22
- Last Posted Date
- 2021-01-15
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 181
- Registration Number
- NCT03382405
- Locations
- 🇺🇸
Advanced Clinical Research, Meridian, Idaho, United States
🇺🇸Optimal Research, Peoria, Illinois, United States
🇺🇸Research Centers of America, Hollywood, Florida, United States
Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects
- Conditions
- Influenza
- Interventions
- Biological: VAL-339851Other: Placebo
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 156
- Registration Number
- NCT03345043
- Locations
- 🇺🇸
Miami Research Associates, Miami, Florida, United States
Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants
- Conditions
- Chikungunya Virus
- Interventions
- Other: PlaceboBiological: VAL-181388
- First Posted Date
- 2017-10-30
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT03325075
- Locations
- 🇺🇸
Optimal Research, Rockville, Maryland, United States
Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies
- Conditions
- Relapsed/Refractory Solid Tumor Malignancies or LymphomaOvarian Cancer
- Interventions
- Biological: mRNA-2416Biological: Durvalumab
- First Posted Date
- 2017-10-27
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 79
- Registration Number
- NCT03323398
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Minnesota Medical Center, Minneapolis, Minnesota, United States
🇺🇸Northwestern Memorial Hospital, Indianapolis, Indiana, United States
Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2017-10-18
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 242
- Registration Number
- NCT03313778
- Locations
- 🇺🇸
Angeles Clinic and Research Institute, Los Angeles, California, United States
🇦🇺Scientia Clinical Research Ltd, Randwick, Australia
🇯🇵National Cancer Center Hospital, Tokyo, Japan